What is MDMA
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic compound first synthesized by Anton Köllisch at Merck in 1912. Pharmacologically, MDMA acts primarily by increasing the release of serotonin,norepinephrine, and dopamine, while also inhibiting their reuptake (Hagino et al, 2011; Rudnick & Wall, 1992). In addition, it stimulates the release of oxytocin, a neurohormone involved in social bonding and interpersonal affiliation (Kirkpatrick et al., 2014).
Interest in MDMA’s therapeutic potential emerged in the late 1970s, when psychotherapists began using it as an adjunct to psychotherapy (Passie, 2018). Early clinical observations suggested that MDMA facilitated the therapeutic process by reducing psychological defensiveness and fear of emotional injury, allowing patients to engage more openly with difficult emotions and experiences. Clinicians also reported that many individuals were able to access and process previously repressed or traumatic memories within a supportive therapeutic setting, often experiencing a reduction in emotional distress (Greer, 1985).
These early observations laid the foundation for the modern scientific investigation of MDMA-assisted psychotherapy, particularly in post-traumatic stress disorder (PTSD). For a more detailed discussion see our dedicated article [https://www.clinicasynaptica.com/es/miedo-trauma-y-mdma/].
How does MDMA facilitate psychotherapy?
During the acute experience, which typically lasts 3–5 hours, individuals generally remain cognitively lucid while experiencing increased emotional openness, empathy, trust, self-compassion, and interpersonal connectedness (Holze et al, 2020; Liechti et al, 2000; Regan et al, 2021).
From a psychotherapeutic perspective, these transient psychological changes may facilitate several processes associated with successful therapeutic outcomes. Increased trust and interpersonal closeness may strengthen the therapeutic alliance, one of the strongest predictors of positive outcomes across psychotherapies (Flückiger et al., 2018; Thal & Lommen, 2018). At the same time, greater emotional openness and reduced psychological defensiveness may allow individuals to approach difficult emotions and autobiographical memories without becoming overwhelmed, fostering deeper emotional processing and self-reflection (Greer, 1985; Greer & Tolbert, 1998).
Rather than acting as a treatment on its own, MDMA appears to create a temporary psychological state that may enhance the effectiveness of psychotherapy when administered within a structured therapeutic protocol.
Beyond PTSD
Although the strongest evidence for MDMA-assisted psychotherapy currently comes from studies on post-traumatic stress disorder (PTSD), its potential is now being explored across a broader range of psychiatric conditions. This growing interest stems from the observation that the psychological processes facilitated by MDMA may be relevant across multiple mental health disorders rather than being specific to PTSD (Harkhoe et al., 2025; Luoma et al., 2022).
Early exploratory studies have focused on conditions such as alcohol use disorder (AUD) and major depressive disorder (MDD). An open-label pilot study in patients with severe AUD found MDMA-assisted psychotherapy to be feasible and well tolerated, with encouraging reductions in alcohol consumption during follow-up (Sessa et al., 2021). Likewise, a proof-of-concept study in patients with MDD reported sustained, long-term reductions in depressive symptoms following treatment (Kvam et al., 2026).
MDMA-assisted psychotherapy has also been investigated in autistic adults with marked to very severe social anxiety. In a small, placebo-controlled pilot study, participants receiving MDMA showed greater improvements in social anxiety than those receiving placebo, with improvements largely maintained at six-month follow-up (Danforth et al., 2018).
Overall, while PTSD remains the primary indication under investigation, these early findings suggest that MDMA-assisted psychotherapy may have broader clinical applications by facilitating psychological processes that extend across traditional diagnostic categories. Nevertheless, larger randomized controlled trials are still needed to establish its efficacy and safety in these conditions.
Despite the promising research, MDMA is not currently approved for therapeutic use in Spain. For this reason, we cannot yet offer MDMA-assisted psychotherapy at our clinic, although we look forward to the possibility of doing so in the future, should it become available for clinical use.
—-
References
Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137–3148. https://doi.org/10.1007/s00213-018-5010-9
Flückiger, C., Del Re, A. C., Wampold, B. E., & Horvath, A. O. (2018). The alliance in adult psychotherapy: A meta-analytic synthesis. Psychotherapy (Chicago, Ill.), 55(4), 316–340. https://doi.org/10.1037/pst0000172
Greer, E. (1985). Using MDMA in psychotherapy. Advances, 2(2), 57–59.
Greer, G. R., & Tolbert, R. (1998). A method of conducting therapeutic sessions with MDMA. Journal of psychoactive drugs, 30(4), 371–379. https://doi.org/10.1080/02791072.1998.10399713
Hagino, Y., Takamatsu, Y., Yamamoto, H., Iwamura, T., Murphy, D. L., Uhl, G. R., Sora, I., & Ikeda, K. (2011). Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters. Current neuropharmacology, 9(1), 91–95. https://doi.org/10.2174/157015911795017254
Harkhoe, M., Offringa, T. & Vermetten, E. Exploring MDMA assisted therapy in eating disorders: mechanisms, clinical evidence, and future directions. J Eat Disord 13, 293 (2025). https://doi.org/10.1186/s40337-025-01409-5
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020). Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 45(3), 462–471. https://doi.org/10.1038/s41386-019-0569-3
Liechti, M. E., Saur, M. R., Gamma, A., Hell, D., & Vollenweider, F. X. (2000). Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 23(4), 396–404. https://doi.org/10.1016/S0893-133X(00)00126-3
Luoma, J. B., Shahar, B., Kati Lear, M., Pilecki, B., & Wagner, A. (2022). Potential processes of change in MDMA-Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships. Human psychopharmacology, 37(3), e2824. https://doi.org/10.1002/hup.2824
Kirkpatrick, M. G., Francis, S. M., Lee, R., de Wit, H., & Jacob, S. (2014). Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology, 46, 23–31. https://doi.org/10.1016/j.psyneuen.2014.04.006
Kvam, T. M., Goksøyr, I. W., Rog, J., van de Vooren, I. J., Stewart, L. H., Autran, I., Berthold-Losleben, M., Mørch-Johnsen, L., Holst, R., Røssberg, J. I., Clausen, I., & Andreassen, O. A. (2026). MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial. Journal of psychiatric research, 193, 302–308. https://doi.org/10.1016/j.jpsychires.2025.11.030
Passie T. The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985). Drug Science, Policy and Law. 2018;4. doi:10.1177/2050324518767442
Regan, A., Margolis, S., de Wit, H., & Lyubomirsky, S. (2021). Does ±3,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis. PloS one, 16(10), e0258849. https://doi.org/10.1371/journal.pone.0258849
Rudnick, G., & Wall, S. C. (1992). The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proceedings of the National Academy of Sciences of the United States of America, 89(5), 1817–1821. https://doi.org/10.1073/pnas.89.5.1817
Sessa, B., Higbed, L., O’Brien, S., Durant, C., Sakal, C., Titheradge, D., Williams, T. M., Rose-Morris, A., Brew-Girard, E., Burrows, S., Wiseman, C., Wilson, S., Rickard, J., & Nutt, D. J. (2021). First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of psychopharmacology (Oxford, England), 35(4), 375–383. https://doi.org/10.1177/0269881121991792
Thal, S. B., & Lommen, M. J. J. (2018). Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. Journal of contemporary psychotherapy, 48(2), 99–108. https://doi.org/10.1007/s10879-017-9379-2
